Page last updated: 2024-08-16

sumatriptan and cromakalim

sumatriptan has been researched along with cromakalim in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Al-Karagholi, MA; Amin, FM; Ashina, M; Ghanizada, H; Hansen, JM; Larsson, HBW; Olesen, J; Skovgaard, LT1
Ashina, M; Christensen, SL; Ernstsen, C; Guo, S; Hay-Schmidt, A; Kristensen, DM; Olesen, J1

Trials

1 trial(s) available for sumatriptan and cromakalim

ArticleYear
Levcromakalim, an Adenosine Triphosphate-Sensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries.
    Headache, 2019, Volume: 59, Issue:9

    Topics: Adult; Cromakalim; Double-Blind Method; Female; Headache; Humans; Ion Channel Gating; Male; Meningeal Arteries; Middle Cerebral Artery; Organ Specificity; Potassium Channels; Sumatriptan; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Young Adult

2019

Other Studies

1 other study(ies) available for sumatriptan and cromakalim

ArticleYear
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
    The journal of headache and pain, 2022, Dec-05, Volume: 23, Issue:1

    Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; Mice; Migraine Disorders; Nitroglycerin; Pituitary Adenylate Cyclase-Activating Polypeptide; Signal Transduction; Sumatriptan

2022